Skip to Content

Oxybutynin Dosage

Applies to the following strength(s): 5 mg/5 mL5 mg5 mg/24 hours10 mg/24 hr15 mg/24 hr3.9 mg/24 hr3%10%

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Geriatric Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Urinary Incontinence

Immediate Release Tablets/Syrup/Solution:
Recommended dose: 5 mg orally 2 to 3 times a day
Maximum dose: 5 mg orally 4 times a day

Extended Release Tablets:
Recommended dose: 5 to 10 mg once a day at approximately the same time each day
Titration: The dose may be adjusted in 5 mg increments at approximately weekly intervals to achieve a balance of efficacy and tolerability
Maximum dose: 30 mg/day

Transdermal System (Patch):
Recommended dose: 3.9 mg/day applied to dry, intact skin on the abdomen, hip, or buttock twice weekly (every 3 or 4 days); a new application site should be selected with each new system to avoid reapplication to the same site within 7 days

Transdermal Gel 3%:
Recommended dose: 3 pumps (84 mg/day) applied once daily to clean, dry, intact skin on the abdomen, or upper arms/shoulders, or thighs; apply immediately after actuating the dose; application sites may be rotated to reduce the potential for local site reactions

Transdermal Gel 10%:
Recommended dose: The contents of one sachet applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs; application sites should be rotated; application should not be made to the same site on consecutive days

Comments:
-Tablets should be swallowed whole, with water.
-In case of a missed dose, the patient should wait and take the next dose at the regular time.
-The patch should be applied to dry, intact skin on the abdomen, hip, or buttock immediately after removal from the protective sachet. A new application site should be selected with each new patch to avoid reapplication to the same site within 7 days.

Uses: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria); overactive bladder; urinary frequency; urinary incontinence

Usual Adult Dose for Urinary Frequency

Immediate Release Tablets/Syrup/Solution:
Recommended dose: 5 mg orally 2 to 3 times a day
Maximum dose: 5 mg orally 4 times a day

Extended Release Tablets:
Recommended dose: 5 to 10 mg once a day at approximately the same time each day
Titration: The dose may be adjusted in 5 mg increments at approximately weekly intervals to achieve a balance of efficacy and tolerability
Maximum dose: 30 mg/day

Transdermal System (Patch):
Recommended dose: 3.9 mg/day applied to dry, intact skin on the abdomen, hip, or buttock twice weekly (every 3 or 4 days); a new application site should be selected with each new system to avoid reapplication to the same site within 7 days

Transdermal Gel 3%:
Recommended dose: 3 pumps (84 mg/day) applied once daily to clean, dry, intact skin on the abdomen, or upper arms/shoulders, or thighs; apply immediately after actuating the dose; application sites may be rotated to reduce the potential for local site reactions

Transdermal Gel 10%:
Recommended dose: The contents of one sachet applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs; application sites should be rotated; application should not be made to the same site on consecutive days

Comments:
-Tablets should be swallowed whole, with water.
-In case of a missed dose, the patient should wait and take the next dose at the regular time.
-The patch should be applied to dry, intact skin on the abdomen, hip, or buttock immediately after removal from the protective sachet. A new application site should be selected with each new patch to avoid reapplication to the same site within 7 days.

Uses: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria); overactive bladder; urinary frequency; urinary incontinence

Usual Adult Dose for Neurogenic Bladder

Immediate Release Tablets/Syrup/Solution:
Recommended dose: 5 mg orally 2 to 3 times a day
Maximum dose: 5 mg orally 4 times a day

Extended Release Tablets:
Recommended dose: 5 to 10 mg once a day at approximately the same time each day
Titration: The dose may be adjusted in 5 mg increments at approximately weekly intervals to achieve a balance of efficacy and tolerability
Maximum dose: 30 mg/day

Transdermal System (Patch):
Recommended dose: 3.9 mg/day applied to dry, intact skin on the abdomen, hip, or buttock twice weekly (every 3 or 4 days); a new application site should be selected with each new system to avoid reapplication to the same site within 7 days

Transdermal Gel 3%:
Recommended dose: 3 pumps (84 mg/day) applied once daily to clean, dry, intact skin on the abdomen, or upper arms/shoulders, or thighs; apply immediately after actuating the dose; application sites may be rotated to reduce the potential for local site reactions

Transdermal Gel 10%:
Recommended dose: The contents of one sachet applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs; application sites should be rotated; application should not be made to the same site on consecutive days

Comments:
-Tablets should be swallowed whole, with water.
-In case of a missed dose, the patient should wait and take the next dose at the regular time.
-The patch should be applied to dry, intact skin on the abdomen, hip, or buttock immediately after removal from the protective sachet. A new application site should be selected with each new patch to avoid reapplication to the same site within 7 days.

Uses: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria); overactive bladder; urinary frequency; urinary incontinence

Usual Geriatric Dose for Urinary Incontinence

Immediate Release Tablets/Syrup/Solution:
Pediatric patients over 5 years of age:
-Usual dose: 5 mg orally 2 times a day
-Maximum dose: 5 mg orally 3 times a day

Extended Release Tablets:
Pediatric patients over 6 years of age:
-Initial dose: 5 mg orally once a day at approximately the same time each day; the dosage may be adjusted in 5 mg increments to achieve a balance of efficacy and tolerability
-Maximum dose: 15 mg orally per day

Comments:
-Tablets should be swallowed whole, with water.
-In case of a missed dose, the patient should wait and take the next dose at the regular time.

Uses:
-Immediate Release Tablets/Syrup/Solution: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria) in patients 5 years of age and older.
-Extended Release Tablets: For the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Usual Geriatric Dose for Urinary Frequency

Immediate Release Tablets/Syrup/Solution:
Pediatric patients over 5 years of age:
-Usual dose: 5 mg orally 2 times a day
-Maximum dose: 5 mg orally 3 times a day

Extended Release Tablets:
Pediatric patients over 6 years of age:
-Initial dose: 5 mg orally once a day at approximately the same time each day; the dosage may be adjusted in 5 mg increments to achieve a balance of efficacy and tolerability
-Maximum dose: 15 mg orally per day

Comments:
-Tablets should be swallowed whole, with water.
-In case of a missed dose, the patient should wait and take the next dose at the regular time.

Uses:
-Immediate Release Tablets/Syrup/Solution: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria) in patients 5 years of age and older.
-Extended Release Tablets: For the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Usual Geriatric Dose for Neurogenic Bladder

Immediate Release Tablets/Syrup/Solution:
Pediatric patients over 5 years of age:
-Usual dose: 5 mg orally 2 times a day
-Maximum dose: 5 mg orally 3 times a day

Extended Release Tablets:
Pediatric patients over 6 years of age:
-Initial dose: 5 mg orally once a day at approximately the same time each day; the dosage may be adjusted in 5 mg increments to achieve a balance of efficacy and tolerability
-Maximum dose: 15 mg orally per day

Comments:
-Tablets should be swallowed whole, with water.
-In case of a missed dose, the patient should wait and take the next dose at the regular time.

Uses:
-Immediate Release Tablets/Syrup/Solution: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria) in patients 5 years of age and older.
-Extended Release Tablets: For the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Usual Pediatric Dose for Urinary Incontinence

Immediate Release Tablets/Syrup/Solution:
Pediatric patients over 5 years of age:
-Usual dose: 5 mg orally 2 times a day
-Maximum dose: 5 mg orally 3 times a day

Extended Release Tablets:
Pediatric patients over 6 years of age:
-Initial dose: 5 mg orally once a day at approximately the same time each day; the dosage may be adjusted in 5 mg increments to achieve a balance of efficacy and tolerability
-Maximum dose: 15 mg orally per day

Comments:
-Tablets should be swallowed whole, with water.
-In case of a missed dose, the patient should wait and take the next dose at the regular time.

Uses:
-Immediate Release Tablets/Syrup/Solution: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria) in patients 5 years of age and older.
-Extended Release Tablets: For the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Usual Pediatric Dose for Urinary Frequency

Immediate Release Tablets/Syrup/Solution:
Pediatric patients over 5 years of age:
-Usual dose: 5 mg orally 2 times a day
-Maximum dose: 5 mg orally 3 times a day

Extended Release Tablets:
Pediatric patients over 6 years of age:
-Initial dose: 5 mg orally once a day at approximately the same time each day; the dosage may be adjusted in 5 mg increments to achieve a balance of efficacy and tolerability
-Maximum dose: 15 mg orally per day

Comments:
-Tablets should be swallowed whole, with water.
-In case of a missed dose, the patient should wait and take the next dose at the regular time.

Uses:
-Immediate Release Tablets/Syrup/Solution: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria) in patients 5 years of age and older.
-Extended Release Tablets: For the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Usual Pediatric Dose for Neurogenic Bladder

Immediate Release Tablets/Syrup/Solution:
Pediatric patients over 5 years of age:
-Usual dose: 5 mg orally 2 times a day
-Maximum dose: 5 mg orally 3 times a day

Extended Release Tablets:
Pediatric patients over 6 years of age:
-Initial dose: 5 mg orally once a day at approximately the same time each day; the dosage may be adjusted in 5 mg increments to achieve a balance of efficacy and tolerability
-Maximum dose: 15 mg orally per day

Comments:
-Tablets should be swallowed whole, with water.
-In case of a missed dose, the patient should wait and take the next dose at the regular time.

Uses:
-Immediate Release Tablets/Syrup/Solution: For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria) in patients 5 years of age and older.
-Extended Release Tablets: For the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).

Renal Dose Adjustments

Caution is recommended

Liver Dose Adjustments

Caution is recommended

Precautions

-Tablet/Syrup/Solution formulation: Safety and efficacy have not been established in patients younger than 5 years.
-Extended-release formulation: Safety and efficacy have not been established in patients younger than 6 years.
-Patch or gel formulation: Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Swallow extended release tablets whole; do not chew, crush, or divide. Extended release tablets may be taken with or without food, at the same time each day.
-The tablet/syrup/solution formulations should be taken with food or milk to decrease GI distress.
-The transdermal system should be applied on the abdomen, hip, or buttock to skin that is dry and intact. Application sites should be rotated to avoid local skin reactions. Do not apply the system to the same site within 7 days.

Monitoring:
-NERVOUS SYSTEM: Monitor for signs of anticholinergic effects in first few months of beginning treatment or increasing dosage.

Patient advice:
-Heat prostration (fever and heat stroke due to decreased sweating) can occur when this drug is administered in the presence of high environmental temperature.
-Patients should be advised to exercise caution because this drug can cause drowsiness (somnolence) or blurred vision.
-Alcohol may enhance the drowsiness caused by this drug.
-In case of a missed dose, the patient should wait and take the next dose at the regular time.
-The extended-release formulation is contained within a nondeformable material that is eliminated from the body and may appear in the stool.
-This drug is associated with anticholinergic central nervous system (CNS) effects, including hallucinations, agitation, confusion, and somnolence.
-Drowsiness and blurred vision may affect mental alertness and work performance. Alcohol and other sedative medications may exacerbate the drowsiness.

Hide